RA0145

antibody from Oursmab

Targeting: CLEC4C BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0145

Provider

Oursmab

Product name

Litifilimab (Biosimilar Reference Antibody) (CLEC4C)

Antibody type

Monoclonal

Description

Litifilimab (also known as BIIB-059) is an investigational, humanized monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2), a receptor exclusively expressed on plasmacytoid dendritic cells (pDCs). By binding to BDCA2, litifilimab triggers the internalization and downregulation of the receptor, leading to the inhibition of pDC activation and the subsequent reduction of type I interferon (IFN) production. Since pDCs are a major source of pathogenic type I IFN in systemic lupus erythematosus (SLE) and other autoimmune diseases, this mechanism aims to dampen a key driver of autoimmunity. It is being clinically evaluated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.